BioMarin Pharmaceutical Inc.
BMRN
$66.05
$0.981.50%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -57.58% | 326.58% | -51.49% | -112.78% | 29.54% |
| Total Depreciation and Amortization | 494.95% | 25.87% | -29.47% | -0.41% | -15.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.29% | -79.42% | 10.62% | 211.00% | 47.54% |
| Change in Net Operating Assets | -239.22% | 123.81% | -237.94% | 175.24% | -74.74% |
| Cash from Operations | -23.81% | 121.44% | -72.97% | 99.00% | 6.24% |
| Capital Expenditure | -37.72% | 48.62% | -43.15% | -66.35% | -1.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.73% | 43,322.41% | 90.03% | -484.19% | 139.31% |
| Cash from Investing | -803.20% | 1,809.18% | 87.17% | -2,528.36% | 55.41% |
| Total Debt Issued | 229.41% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 96,271.43% | -99.91% | -- |
| Repurchase of Common Stock | 59.82% | -943.70% | -24.08% | 82.32% | 68.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -558.16% | -873.34% | -- | -- | -- |
| Cash from Financing | 236.75% | 25,657.59% | 245.55% | 52.88% | 88.13% |
| Foreign Exchange rate Adjustments | -315.60% | 15.67% | 64.95% | 124.13% | -116.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.86% | 2,759.72% | 69.65% | -78.01% | 55.73% |